Compare Trade Desk Inc (TTD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trade Desk Inc vs GeneDx Holdings Corp — how do they compare? Trade Desk Inc trades at $13.9 (market cap $6.52B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Trade Desk Inc is far larger — about 2.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| TTD | WGS | |
|---|---|---|
Market Cap | $6.52B | $2.58B |
Sector | Technology | Technology |
52-Week High | $54.13 | $167.51 |
52-Week Low | $13.03 | $34.51 |
Enterprise Value | $5.47B | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Trade Desk (TTD) trades at $14.02, down 2.84% on the day and near its 52-week lows, reflecting significant year-to-date pressure. Recent financials show revenue growth slowing to 3% in Q2 2026 with earnings misses, while the company undergoes a 15% workforce restructuring. Technical indicators signal a bearish trend with mixed momentum oscillators. Despite strong profitability margins, valuation multiples remain compressed amid weak advertising demand and competitive pressures.
Outlook remains cautious with near-term headwinds from soft ad spending and execution risks from restructuring. Long-term opportunities exist in CTV and AI-driven ad platforms, but investor sentiment is divided with analysts showing mixed ratings. The stock trades below consensus price targets, offering potential upside if operational improvements materialize, though volatility may persist.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
